Clinical Trial Update: Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS) [NA]

View source ↗

Summary

The trial evaluating nocturnal PtcCO2 monitoring in patients with Amyotrophic Lateral Sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Snippet

Sponsor: Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | Conditions: Amyotrophic Lateral Sclerosis | NA | Status: COMPLETED